TLR7 modulates glioblastoma progression through PI3K/AKT/mTOR pathway and immune microenvironment remodeling
- 13 December 2025
- journal article
- research article
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 195 (2) , 597-607
Abstract
Background Glioblastoma (GBM) is an aggressive brain tumor, necessitating the identification of new therapeutic targets. Toll-like receptor 7 (TLR7), a key component of innate immunity, influences oncological processes, but its role in GBM is unclear. This study investigates the impact of TLR7 overexpression on GBM and its underlying mechanisms. Methods Glioblastoma cell lines (U87 and U251) were transfected with a pcDNA-TLR7 plasmid to induce overexpression, verified by qRT-PCR. Proliferation was assessed using CCK-8 and colony formation assays. Migration and invasion were evaluated via Transwell and wound healing assays. Activation of the PI3K/AKT/mTOR signaling pathway was analyzed by Western blotting. Macrophage polarization was studied by exposing M0 macrophages to the TLR7 agonist R837, followed by qRT-PCR and cytokine quantification. Results TLR7 was successfully overexpressed in U87 and U251 cells. TLR7 overexpression significantly reduced GBM cell proliferation, colony formation, migration, and invasion. It suppressed the PI3K/AKT/mTOR signaling pathway. In the tumor microenvironment, TLR7 promoted M1 macrophage polarization, increasing M1 markers and pro-inflammatory cytokines while suppressing M2 markers. Conclusion TLR7 suppresses glioblastoma by inhibiting cell progression via the PI3K/AKT/mTOR signaling pathway and promoting an anti-tumoral immune microenvironment. These findings suggest the potential of TLR7 as a promising therapeutic target for GBM.Keywords
This publication has 33 references indexed in Scilit:
- PLD1 is a key player in cancer stemness and chemoresistance: Therapeutic targeting of cross-talk between the PI3K/Akt and Wnt/β-catenin pathwaysExperimental & Molecular Medicine, 2024
- A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancerInternational Immunopharmacology, 2024
- Challenges in glioblastoma research: focus on the tumor microenvironmentTrends in Cancer, 2022
- An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatmentCancer Communications, 2022
- Single‐cell RNA Sequencing Identified Novel Nr4a1+ Ear2+ Anti‐Inflammatory Macrophage Phenotype under Myeloid‐TLR4 Dependent Regulation in Anti‐Glomerular Basement Membrane (GBM) Crescentic Glomerulonephritis (cGN)Advanced Science, 2022
- The potential of glycyrrhizin and licorice extract in combating COVID-19 and associated conditionsPhytomedicine Plus, 2021
- Secondary cvd prevention—Lipid modification strategies: A critical analysisDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2017
- The concentration of desflurane preventing spectral entropy change during surgical stimulation: A prospective randomized trialJournal of Clinical Anesthesia, 2017
- Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapyNature Communications, 2016
- Holocene oscillations in temperature and salinity of the surface subpolar North AtlanticNature, 2009